Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:36:18 2024-06-27 EDT 5-day change 1st Jan Change
89.86 EUR -1.02% Intraday chart for Sanofi +3.50% +0.11%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
CAC40: caution prevails ahead of crucial deadlines CF
CAC40: consolidates solo, OAT/Bund spread widens to 81Pb CF
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT
Top Premarket Gainers MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment DJ
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study MT
CAC40: below 7600 pts, held back by the automotive sector CF
Vigil Neuroscience Receives $40 Million Investment From Sanofi MT
The same old winners Our Logo
Sanofi: positive publication for Dupixent in NEJM CF
Sanofi Partakes in Formation Bio's $372 Million Fundraising MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine CI
FDA approves Verona Pharma's therapy for 'smoker's lungs' RE
Sanofi-backed Drug Developer Formation Bio Raises $372 Million MT
Sanofi-backed Formation Bio raises $372 million in late-stage funding round RE
Euroapi: updated outlook for 2024 CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports DJ
Sanofi Invites Initial Bids for $20 Billion Consumer Spinoff MT
TrialSpark, Inc. announced that it has received $372 million in funding from a group of investors CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sanofi Progresses on Consumer Health Separation; Sale, Spinoff Still on Table MT
US CDC alerts healthcare providers of increase in dengue cases RE
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.86 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.40%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. US FDA Accepts Sanofi's New Drug Application for Hemophilia Treatment Fitusiran